UNITED THERAPEUTICS Corp (UTHR) stock
UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3022% above fair value
$584.10−3.78 (-0.64%)
Close on Nov 17, 2026Market cap $25.05BP/E 20.9Yield –
United Therapeutics cash
Cash and short-term investments held at the end of each period.
United Therapeutics's cash was $2.66B at Jun 30, 2026. For fiscal 2025 it was $2.92B, down 10.6% from the year before. Over ten years it grew 13.4% a year on average. The highest annual figure on record is $3.27B in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.92B | -10.6% |
| FY2024 | Dec 31, 2024 | $3.27B | +9.1% |
| FY2023 | Dec 31, 2023 | $2.99B | +5.5% |
| FY2022 | Dec 31, 2022 | $2.84B | +47.0% |
| FY2021 | Dec 31, 2021 | $1.93B | +5.2% |
| FY2020 | Dec 31, 2020 | $1.84B | +23.5% |
| FY2019 | Dec 31, 2019 | $1.49B | +4.9% |
| FY2018 | Dec 31, 2018 | $1.42B | +52.7% |
| FY2017 | Dec 31, 2017 | $927.40M | -11.7% |
| FY2016 | Dec 31, 2016 | $1.05B | +26.3% |
| FY2015 | Dec 31, 2015 | $831.80M | +109.2% |
| FY2014 | Dec 31, 2014 | $397.70M | +39.9% |
| FY2013 | Dec 31, 2013 | $284.30M | +78.4% |
| FY2012 | Dec 31, 2012 | $159.40M | -5.1% |
| FY2011 | Dec 31, 2011 | $168.05M | -33.4% |
| FY2010 | Dec 31, 2010 | $252.16M | +151.3% |
| FY2009 | Dec 31, 2009 | $100.35M | -22.5% |
| FY2008 | Dec 31, 2008 | $129.45M | -7.1% |
| FY2007 | Dec 31, 2007 | $139.32M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.66B | -12.7% |
| Q1 FY2026 | Mar 31, 2026 | $2.15B | -35.2% |
| Q4 FY2025 | Dec 31, 2025 | $2.92B | -10.6% |
| Q3 FY2025 | Sep 30, 2025 | $2.77B | -16.8% |
| Q2 FY2025 | Jun 30, 2025 | $3.05B | +2.6% |
| Q1 FY2025 | Mar 31, 2025 | $3.32B | +22.7% |
| Q4 FY2024 | Dec 31, 2024 | $3.27B | +9.1% |
| Q3 FY2024 | Sep 30, 2024 | $3.33B | +15.7% |
| Q2 FY2024 | Jun 30, 2024 | $2.97B | +10.9% |
| Q1 FY2024 | Mar 31, 2024 | $2.71B | -5.4% |
| Q4 FY2023 | Dec 31, 2023 | $2.99B | +5.5% |
| Q3 FY2023 | Sep 30, 2023 | $2.88B | +9.9% |
| Q2 FY2023 | Jun 30, 2023 | $2.68B | +18.8% |
| Q1 FY2023 | Mar 31, 2023 | $2.86B | +26.3% |
| Q4 FY2022 | Dec 31, 2022 | $2.84B | +47.0% |
| Q3 FY2022 | Sep 30, 2022 | $2.62B | +30.8% |
| Q2 FY2022 | Jun 30, 2022 | $2.26B | +14.6% |
| Q1 FY2022 | Mar 31, 2022 | $2.27B | +31.0% |
| Q4 FY2021 | Dec 31, 2021 | $1.93B | +5.2% |
| Q3 FY2021 | Sep 30, 2021 | $2.00B | +26.6% |
| Q2 FY2021 | Jun 30, 2021 | $1.97B | +26.1% |
| Q1 FY2021 | Mar 31, 2021 | $1.73B | +12.1% |
| Q4 FY2020 | Dec 31, 2020 | $1.84B | +23.5% |
| Q3 FY2020 | Sep 30, 2020 | $1.58B | +0.7% |
| Q2 FY2020 | Jun 30, 2020 | $1.56B | -12.6% |
| Q1 FY2020 | Mar 31, 2020 | $1.54B | -3.8% |
| Q4 FY2019 | Dec 31, 2019 | $1.49B | +4.9% |
| Q3 FY2019 | Sep 30, 2019 | $1.57B | +26.9% |
| Q2 FY2019 | Jun 30, 2019 | $1.79B | +47.3% |
| Q1 FY2019 | Mar 31, 2019 | $1.61B | +27.7% |
| Q4 FY2018 | Dec 31, 2018 | $1.42B | +52.7% |
| Q3 FY2018 | Sep 30, 2018 | $1.24B | +2.2% |
| Q2 FY2018 | Jun 30, 2018 | $1.21B | +8.8% |
| Q1 FY2018 | Mar 31, 2018 | $1.26B | +8.7% |
| Q4 FY2017 | Dec 31, 2017 | $927.40M | -11.7% |
| Q3 FY2017 | Sep 30, 2017 | $1.21B | +27.0% |
| Q2 FY2017 | Jun 30, 2017 | $1.12B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.16B | – |
| Q4 FY2016 | Dec 31, 2016 | $1.05B | – |
| Q3 FY2016 | Sep 30, 2016 | $953.00M | – |
See a number that looks wrong?